Significantly, researchers discovered that the combination therapy of mIDH1 inhibitor AG120 (an orally active inhibitor of mIDH1 enzyme) and anti-CTLA-4 antibody induced substantial cell death and sustained tumor-specific T-cell responses in tumor-bearing mice [84]. Here, CTLA4 is linked to neoplasm.